Kynurenic acid
KYNA
What it isTryptophan metabolite acting as an NMDA glycine-site antagonist and GPR35 agonist.
Why this oneIts elevation in schizophrenia is a leading hypothesis for the glutamatergic model of the illness.
What limits itIt is why kynurenine pathway enzymes became drug targets, though nothing has yet reached practice.
NO BOXED WARNINGS
Principal riskEndogenous or dietary; no boxed warning applies
Classes and tags
Clinical profile
Mechanism of action: Kynurenic acid ballicule
Open Kynurenic acid in the interactive console ↗
Memory aids: mascots and interaction avatars
